Iterum Therapeutics Plc Stock Today
| ITRM Stock | USD 1.44 0.01 0.69% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Iterum Therapeutics is selling at 1.44 as of the 22nd of March 2025; that is 0.69 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.42. Iterum Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of May 2018 | Category Healthcare | Classification Health Care |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 34.58 M outstanding shares of which 1.85 M shares are currently shorted by private and institutional investors with about 2.75 trading days to cover. More on Iterum Therapeutics PLC
Moving together with Iterum Stock
| 0.77 | DSGN | Design Therapeutics | PairCorr |
| 0.87 | EYEN | Eyenovia | PairCorr |
| 0.9 | CGC | Canopy Growth Corp | PairCorr |
| 0.61 | MRK | Merck Company | PairCorr |
Moving against Iterum Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Iterum Stock Highlights
| CEO, Director | Corey Fishman | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIterum Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iterum Therapeutics' financial leverage. It provides some insight into what part of Iterum Therapeutics' total assets is financed by creditors.
| |||||
Iterum Therapeutics PLC (ITRM) is traded on NASDAQ Exchange in USA. It is located in 3 Dublin Landings, Dublin, Ireland, D01 C4E0 and employs 9 people. Iterum Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.14 M. Iterum Therapeutics PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 34.58 M outstanding shares of which 1.85 M shares are currently shorted by private and institutional investors with about 2.75 trading days to cover.
Iterum Therapeutics PLC currently holds about 68.91 M in cash with (26.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Iterum Therapeutics Probability Of Bankruptcy
Ownership AllocationIterum Therapeutics PLC has a total of 34.58 Million outstanding shares. Roughly 90.29 (percent) of Iterum Therapeutics outstanding shares are held by general public with 1.18 % owned by insiders and only 8.53 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Iterum Ownership Details
Iterum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 3.1 K | |
| Tower Research Capital Llc | 2024-12-31 | 710 | |
| Barclays Plc | 2024-12-31 | 500 | |
| Activest Wealth Management | 2024-12-31 | 133 | |
| Wells Fargo & Co | 2024-12-31 | 85.0 | |
| Cypress Capital Management, Llc | 2024-12-31 | 66.0 | |
| Planning Capital Management Corp | 2024-09-30 | 40.0 | |
| Newbridge Financial Services Group, Inc. | 2024-12-31 | 15.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 14.0 | |
| Renaissance Technologies Corp | 2024-12-31 | 438.8 K | |
| New Leaf Venture Partners, L.l.c. | 2024-12-31 | 345 K |
Iterum Therapeutics Historical Income Statement
Iterum Stock Against Markets
Iterum Therapeutics Corporate Management
| Sailaja MD | Chief Officer | Profile | |
| Tom Loughman | Senior Operations | Profile | |
| Steven MD | Senior Development | Profile | |
| Louise Barrett | Senior Secretary | Profile | |
| Michael MD | Strategic Director | Profile | |
| Judith Matthews | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.